Funding coup for rare diseases researchers November 19, 2012 Hundreds of thousands of people Australia-wide are expected to benefit from a major funding grant to be administered by Murdoch University for rare diseases research. Announcing the $989,884 grant, WA Health’s Director of Population Health Genomics, Dr Hugh Dawkins said the money would be used to link information on rare diseases from around the world. Also an Adjunct with Murdoch University’s Centre for Comparative Genomics (CCG), Dr Dawkins said around one in 12 Australians had a rare disease such as Muscular Dystrophy, Cystic Fibrosis, Huntington’s, Motor Neurone or early-onset Alzheimer’s. “More than 6000 conditions – most known to be inherited genetically – are classified as rare diseases because they affect fewer than one in 2000 people,” he said. “While rare diseases are quite prevalent in the community, some of them only affect as few as one family – or one person – in Australia, and many do not even have their own medical code for classification. “This research grant will help build a database of these rare diseases. “By systematically pooling together information, including clinical and genetic information and research and trial datasets from across Australia and around the world, it is hoped that researchers will have more to work with.” Dr Dawkins said rare diseases were often referred to as orphan diseases because they provided little financial incentive for pharmaceutical companies to invest in or ‘adopt’ them. “With so few cases to study, researchers also have less data with which to work,” he said. “This not only limits our knowledge of these diseases but clinicians’ ability to manage individuals living with a rare disease.” Dr Dawkins said the National Health and Medical Research Council – European Union (NHMRC-EU) Collaborative Research Grant would be coordinated by WA Health and administered by Murdoch University over a five year period. “The project that has received the funding – RD Connect – is a collaborative project,” he said. “Research partners include the Centre for Comparative Genomics and the Institute for Immunology and Infectious Diseases at Murdoch University and Genetic Services at King Edward Memorial Hospital. “Other collaborating partners include Royal Perth Hospital, the University of Western Australia, Edith Cowan University, the University of Melbourne and the University of Queensland. “RD-Connect will become an important resource for rare disease researchers worldwide and help further knowledge and treatment of rare diseases. “Ultimately it will lead to better outcomes for people with rare diseases.” Print This Post Media contact: Rob Payne Tel: (08) 9360-2491 | Mobile: | Email: firstname.lastname@example.org Categories: General, Teaching and Learning, Future Students, International students, Murdoch achievements, Research Tags: alzheimers, ccg, centre for comparative genomics, cystic fibrosis, ecu, hugh dawkins, huntington's, iiid, institute for immunology and infectious diseases, king edward memorial hospital, matthew bellgard, motor neurone, muscular dystrophy, national health and medical research council - european union collaborative research grant, population health genomics, rare diseases, rare voices australia, university of melbourne, university of queensland, uwa, wa health Comments (One response) Maureen October 23, 2013 I am very happy to see that there is funding for rare diseases. Although Alzheimer's disease and cardiovascular diseases are very prevalent, people with rare diseases need as much medical resources/research effort as people with common diseases. Hope in the near future that people can understand the importance of biomedical research. How do you recruit patients? How do you link rare diseases around the globe as the article described since there isn't any database around? Leave a comment Name (required) Mail (will not be published) (required) Website You can use these tags : <a href="" title=""> <abbr title=""> <acronym title=""> <b> <blockquote cite=""> <cite> <code> <del datetime=""> <em> <i> <q cite=""> <s> <strike> <strong> We read every comment and will make every effort to approve each new comment within one working day. To ensure speedy posting, please keep your comments relevant to the topic of discussion, free of inappropriate language and in-line with the editorial integrity of this newsroom. If not, your comments may not be published. Thanks for commenting!